Important information about BUCCOLAM® (midazolam) oromucosal solution: Neuraxpharm UK has made some important changes to the BUCCOLAM® protective capped plastic tube. From October 2022 you will notice that the self-adhesive strap (‘seal’) on the tube has been removed. Please click here to read further.
Therapeutic indications: Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years).
Click here for complete product code information.
Follow the link to access our extensive range of free Buccolam® training resources.
ADVERSE EVENTS SHOULD BE REPORTED
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Neuraxpharm UK Ltd by:
- Email: pv-uk@neuraxpharm.com
- Phone number: +44 330 128 0919